Table 1.
Patient characteristics.
| Demographics | Healthy volunteers (n = 12) | Patients (n = 25) |
|---|---|---|
| Age (years) | 56 ± 5 | 65 ± 9* |
| Sex (female) | 4 (33%) | 3 (12%) |
| Body mass index (kg/m2) | 24.4 ± 2.1 | 28.0 ± 4.6* |
| Body weight (kg) | 72.5 ± 10.4 | 85.3 ± 16.2* |
| Global left ventricular CMR measures | ||
| Mass index (g/m2) | 75 ± 15 | 68 ± 10 |
| End-diastolic volume index (ml/m2) | 86 ± 16 | 72 ± 15 |
| End-systolic volume index (ml/m2) | 32 ± 7 | 27 ± 11 |
| Stroke volume index (ml/m2) | 54 ± 11 | 44 ± 11 |
| Ejection fraction (%) | 63 ± 5 | 62 ± 10 |
| Cardiac index (L/min/m2) | 3.1 ± 0.7 | 2.9 ± 0.8 |
| Peak strainSAXstack (%) | −20.4 ± 3.6 | −19.3 ± 1.9 |
| Native T1 mapping (ms) | 1,209 ± 41 | 1,228 ± 51 |
| T2 mapping (ms) | 39.2 ± 1.8 | 39.6 ± 2.4 |
| Coronary risk factors | ||
| Dyslipidemia | – | 17 (68%) |
| Hypertension | – | 14 (56%) |
| Diabetes mellitus | – | 8 (32%) |
| Sleep apnea syndrome | – | 3 (12%) |
| Medication | ||
| Aspirin | – | 25 (100%) |
| Statins | – | 22 (88%) |
| Dual anti-platelet therapy | – | 21 (84%) |
| Beta-blockers | – | 18 (72%) |
| Angiotensin-converting enzyme inhibitors | – | 9 (36%) |
| Angiotensin receptor blocker | – | 7 (28%) |
| Calcium channel blocker | – | 4 (16%) |
Baseline characteristics of the study subjects at the time of CMR exam. Data reported as mean ± SD or n (%).
*
p < 0.05 between groups.